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Abstract
The aim of this study was to characterize the oncogenic function and mechanism of Cathepsin Z (CTSZ) at 20q13.3, a
frequently amplified region in hepatocellular carcinoma (HCC). Real-time PCR were used to compare CTSZ expression
between paired HCC tumor and non-tumor specimens. CTSZ gene was stably transfected into HCC line QGY-7703 cells and
its role in tumorigenicity and cell motility was characterized by soft agar, wound-healing, transwell invasion and cell
adhesion assay, and tumor xenograft mouse model. Western blot analysis was used to study expression of proteins
associated with epithelial-mesenchymal transition (EMT).
Upregulation of CTSZ was detected in 59/137 (43%) of primary HCCs, which was significantly associated with advanced
clinical stage (P=0.000). Functional study found that CTSZ could increase colony formation in soft agar and promote cell
motility. Further study found that the metastatic effect of CTSZ was associated with its role in inducing epithelial-
mesenchymal transition (EMT) by upregulating mesenchymal markers (fibronectin and vimentin) and downregulating
epithelial markers (E-cadherin and a-catenin). In addition, CTSZ could also upregulate proteins associated with extracellular
matrix remodeling such as MMP2, MMP3 and MMP9. Taken together, our data suggested that CTSZ was a candidate
oncogene within the 20q13 amplicon and it played an important role in HCC metastasis.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most malignant
cancers especially in Asian countries, and its poor prognosis is
mainly due to metastasis after excision [1]. Genomic aberration,
which leads to altered expression of genes within the aberration
region, contributes greatly to the hepatocarcinogenesis. Using
comparative genomic hybridization (CGH), chromosomal alter-
ations including gain of 1q, 6q, 8q, 17q and 20q, and loss of 4q,
8p, 13q, 16q and 17p have been frequently detected in HCC [2–
4]. It is believed that frequently amplified region may contain one
or more oncogenes that play important roles in cancer
development and progression. Identification and characterization
of oncogene is one of the key issues in understanding the
mechanism of tumor development and developing therapies
against cancers [5]. Oncogenes often encode proteins that
participate in signal transduction and intracellular signaling and
can be activated mainly by overexpression, which can be
accomplished in a number of ways including gene amplification.
In this study, a cathepsin family member cathepsin Z (CTSZ),
located in a frequently amplified region at 20q13.3, which is
related to the enhancement of metastasis in various cancers [6],
was identified to be upregulated in 43% of HCC samples. CTSZ
was also reported to be upregulated in gastric cancer and play a
role in tumor development [7]. However the role of CTSZ in HCC
metastasis has not been studied till now. In the present study, we
found that CTSZ had a strong oncogenic ability and was able to
increase cell motility and promote metastasis through the
downregulation of epithelial markers E-cadherin and a-catenin,
and upregulation of mesenchymal markers fibronectin and
vimentin. In addition, CTSZ could upregulate expressions of
MMP2, MMP3 and MMP9, which have been reported as
metastasis contributors through their protease function targeting
the extracellular matrix [8].
Results
CTSZ is frequently upregulated in HCC and the
upregulation is correlated with poor survival of HCC
patients
CTSZ mRNA expression level was examined in 137 pairs of
human HCC and their corresponding nontumorous liver tissues
by qPCR. The result found that the upregulation of CTSZ was
detected in 59/137 (43.7%) of the HCC cases, compared with
their paired nontumorous liver tissues. The RQ of CTSZ in tumor
and nontumor were then subjected to the following statistical
analysis, and the result confirmed that the expression level of
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24967CTSZ was significantly higher in tumor tissues than that in their
paired nontumorous liver tissues (P=0.000, n=137, Fig. 1a). The
upregulation of CTSZ was also observed in the protein level by
western blot assay, representative results were shown in Fig. 1b.
Using immunohistochemistry method, we were able to determine
the subcellular localization of CTSZ in HCC tissues. As shown in
Fig. 1c, CTSZ staining was only found in liver cells, no staining
can be found in the surrounding lymphocytes despite of their
abundant existence. Using Kaplan-Meier method, overall survival,
disease free survival, 5-year survival and 3-year survival of patients
with or without CTSZ upregulation were compared. The results
showed that the upregulation of CTSZ was significantly correlated
with poorer 5-year (P=0.014, Fig. 1f) and 3-year (P=0.022,
Fig. 1g) survival of HCC patients. Although not significant, CTSZ
overexpression was still correlated with shorter overall survival
(Fig. 1d) and disease free survival (Fig. 1e) time of HCC patients,
and the reason of not significant correlation with disease free
survival maybe due to some disease free survival information was
not available.
Overexpression of CTSZ correlates with advanced tumor
stage
The correlation between CTSZ upregulation and clinical-
pathological features including gender, age, HBsAg, serum AFP,
tumor size, cirrhosis, adjacent organs invasion, reccurrence or
metastasis, tumor encapsulation and tumor stage were studied.
The result showed that the upregulation of CTSZ was significantly
associated with the serum AFP (P=0.001, Table 1). CTSZ
upregulation was also found to be significantly correlated with
advanced tumor stage (P=0.000, Table 1). Although we failed to
found significant correlation between CTSZ upregulation and
metastasis related features, we did found that higher percentage
(51%) of patients without tumor encapsulation has got CTSZ
upregulation than that (34.8%) of patients with encapsulation
(Table 1).
Overexpression of CTSZ increases the colony formation
in soft agar
To investigate the oncogenic ability of CTSZ, CTSZ was stably
transfected into QGY-7703 cells and its expression was confirmed
by RT-PCR (Fig. 2a). Cell growth assay showed that the cell
growth rate was similar between CTSZ-7703 and Vec-7703 cells
(Fig. 2b). Soft agar assay showed that the frequencies of colony
formation in CTSZ-transfectants were significantly higher than
that in Vec-7703 cells (P,0.05, Fig. 2c).
CTSZ enhances cell migration and invasion while reduces
cell adhesion
To investigate the effect of CTSZ overexpression on cell
invasion, transwell invasion assay was performed using chamber
coated with a thin layer of extracellular matrix, and the results
showed that overexpression of CTSZ substantially enhanced the
invasiveness of HCC cells, as indicated by a marked increase in the
number of invaded cells (Fig. 3a). In addition, we found that
CTSZ-7703 cells displayed a significant increase in cell migration
ability compared with Vec-7703 cells by wound healing assay
(Fig. 3b). Cell adhesion assay also found that both CTSZ-
transfectants exhibited significant decreased adhesive ability
compared to the vector-transfected cells at 30 mins timepoint
(Fig. 3c), although the difference at 1 hour time point was no
longer significant. This phenomenon was reasonable for that all
the cells would attach at last.
CTSZ promotes tumor metastasis in SCID mice
To further study the in vivo effect of CTSZ overexpression on
tumor metastasis, an experimental metastasis assay was used to
compare the metastatic nodules formed in lungs and livers of
SCID mice following inoculation with CTSZ-7703 cells or Vec-
7703 cells by tail vain injection. One month after injection, mice
were sacrificed and lungs and livers were captured. No metastatic
nodules were found in lungs in all tested animals. However,
metastatic nodules on the surface of the liver was only observed in
CTSZ-7703 cells, suggesting that CTSZ conferred the cells higher
mobility which enabled them to extravasate from circulation and
form metastatic nodules in liver (Fig. 3d). Histological studies
confirmed that the lesions were caused by the extravasation, and
the subsequent tumor growth of CTSZ-transfected HCC cells into
the livers (Fig. 3d).
CTSZ promotes metastasis by inducing EMT
To explore the mechanism through which CTSZ conferred
higher mobility on QGY-7703 cells, expression of epithelial
markers (E-cadherin, a-catenin and b-catenin) and mesenchymal
markers (Fibronectin, N-cadherin) were analyzed by Western
blotting and immunofluorescence assays (IF). Western blot analysis
showed that E-cadherin and a-catenin, and b-catenin were
downregulated, while Fibronectin and N-cadherin was upregu-
lated in CTSZ-7703 cells compared with Vec-7703 cells (Fig. 4a).
Consistent with Western blotting data, downregulation of E-
cadherin and a-catenin, and upregulation of Vimentin were also
detected in CTSZ-7703 cells by IF (Fig. 4b). Interestingly, the
morphology of CTSZ-7703 cells was changed from circular-like
epithelial cells to elongated spindle-like mesenchymal cells, which
also contributed to the elevated cell mobility (Fig. 4c). In addition,
isothiocyanate conjugated phalloidin staining found that CTSZ-
7703 cells formed philopodia.
Overexpression of CTSZ upregulates MMP2, MMP3 and
MMP9
As shown above, overexpression of CTSZ reduced cell
adhesion, suggesting some of extracellular matrix remodeling
proteins such as MMPs might be upregulated by CTSZ.
Compared to Vec-7703 cells, upregulations of MMP2, MMP3
and MMP9 were detected in CTSZ-7703 cells by qPCR (Fig. 4d).
MMP9 upregulation in CTSZ-C1 and CTSZ-C1 was further
confirmed by western blot (Fig. 4e). MMP9 was shown as double
bands here, and from previous study we know that the smaller
band which is around 75KD represents the active form of MMP9.
So the results here showed that not only MMP9 was upregulated
in the CTSZ overexpressed cell line, but the active form of MMP9
also increased.
Discussion
In this study, we found that CTSZ, within a frequently
amplified region at 20q13.2, was frequently upregulated in
HCC. Ectopic expression of CTSZ could increase cell motility,
implying that CTSZ might play an important role in HCC
invasion and metastasis. Metastasis is a multistep process which
contains migration to adjacent tissue, intravasation to circulation,
survival in circulation, extravasation to secondary tissues, and
colony formation at the secondary tissues [9]. Factors affect one or
more steps may finally enhance or inhibit the outcome of
metastasis. The mechanism that initiates or promotes tumor
metastasis has long been a key issue being studied for developing
more effective therapies. Among those metastasis-related genes,
cathepsin family members stand out by playing unique roles.
CTSZ Promotes HCC Metastasis
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associated with cancer progression. Cathepsin B promotes
progression and metastasis in mammary cancer, and the enhanced
expression of cathepsin inhibitor Stefin A inhibits distant
metastasis in primary breast cancer [10]. Cathepsin D is an
independent marker of poor prognosis in breast cancer correlated
Figure 1. CTSZ is frequently upregulated in HCC. (a) The expression level of CTSZ relative to 18S rRNA was compared between nontumorous
and tumor tissues in 137 HCCs using quantitative PCR. Expression of CTSZ in tumor tissues was significantly higher than that in nontumorous tissues
(P=0.000, n=137). (b) Representative pictures of CTSZ protein expression in randomly selected paired HCC nontumor and tumor tissues, GAPDH was
used as endogenous control. CTSZ was upregulated in most of the HCC tumor tissues compared to paired nontumor tissues. (c) Representative
pictures of immunohistochemistry results of CTSZ subcellular localization. N: nontumor, T: tumor. Upregulation of CTSZ in tumor tissues was again
found and the staining was only observed in liver cells rather than the surrounding lymphocytes. Overall Survival (d), disease free survival (e), 5-year
survival (f) and 3-year survival (g) of HCC patients with or without CTSZ upregulation were compared using Kaplan-Meier method. Results indicated
that the upregulation of CTSZ was significantly correlated to worse prognosis and shortened survival (P=0.024).
doi:10.1371/journal.pone.0024967.g001
Table 1. Clinico-pathological Correlation of CTSZ Expression in HCC.
CTSZ expression
Clinicopathological features Number (n) Not upregulated upregulated P
*
Gender
Male 115 64 (55.7%) 51 (44.3%)
Female 22 14 (63.6%) 8 (36.4%) 0.326
Age
,60 108 60 (55.6%) 48 (44.4%)
.=60 29 18 (62.1%) 11 (37.9%) 0.340
HbsAg
{
Negative 30 20 (66.7%) 10 (33.3%)
Positive 89 46 (51.7%) 43 (48.3%) 0.112
Serum AFP (ng/ml)
1
,500 69 30 (43.5%) 39 (56.5%)
.=500 49 36 (73.5%) 13 (26.5%) 0.001
Tumor size (cm)
{,1
,5 36 21 (58.3%) 15 (41.7%)
.=5 85 46 (54.1%) 39 (45.9%) 0.694
Cirrhosis
1
Absent 39 22 (56.4%) 17 (43.6%)
Mild 35 18 (51.4%) 17 (48.6%)
Moderate 31 19 (61.3%) 12 (38.7%)
Severe 11 8 (72.7%) 3 (27.3%) 0.621
Adjacent Organs Invasion
1
Negative 81 49 (48.2%) 32 (51.8%)
Positive 43 27 (38.9%) 16 (61.1%) 0.848
Reccurrence or metastasis
1
Negative 79 47 (60.5%) 32 (39.5%)
Positive 45 29 (64.4%) 16 (35.6%) 0.702
Tumor encapsulation
1
Absent 51 25 (49.0%) 26 (51.0%)
Present 66 43 (65.2%) 23 (34.8%) 0.091
Tumor stage (TNM)
1
Stage I 55 38 (69.1%) 17 (30.9%)
Stage II 29 7 (24.1%) 22 (75.9%)
Stage III 35 21 (60.0%) 14 (40.0%) 0.000
*: Two-sided x
2 test.
{: Hepatitis B surface antigen;
{: Tumor size was measured by the length of the largest tumor nodule;
1: Partial data is not available, and statistic was based on available data;
doi:10.1371/journal.pone.0024967.t001
CTSZ Promotes HCC Metastasis
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24967with the incidence of clinical metastasis [11], and downregulation
of Cathepsin D inhibits tumor growth and experimental metastasis
of human breast cancer cells [12]. In osteosarcoma, Cathepsin K
has been identified as an indicator of metastasis, and patients with
lower expression of Cathepsin K have better prognosis [13].
Although with some limitations that this study was conducted by
ectopic overexpression system, but not an inducible system, our
results of CTSZ promoting cell metastasis remains consistent with
other studies recently. Sevennich and colleagues proved that
combined inhibition of Cathepsin B and Cathepsin Z inhibited
breast cancer metastasis in mice [14]. Kraus et al found
downregulation of Cathepsin X induced cellular senescence and
inhibition of cell invasion as well [15]. A cDNA microarray study
also illustrated that CTSZ was one of those upregulated genes
related with melanoma malignancy [16]. In our study, introduc-
tion of CTSZ into HCC cell line QGY-7703 could induce the
conversion of cobblestone-like epithelial morphology into spindle-
shape mesenchymal morphology. These morphological and cell-
cell contact changes might ultimately reflect on cell mobility and
invasive ability. Consistent with the morphological change, some
hallmark proteins of epithelial cells including E-cadherin, a-
catenin and beta b-catenin have been reduced, meanwhile the
mesenchymal cell markers fibronectin and N-cadherin have been
upregulated. These results strongly suggested that the increasing
motility conferred by CTSZ was via EMT. EMT was originally
recognized as a critical step to metazoan embryogenesis and in
defining structures during organ development. In the past decade,
EMT has arisen to be recognized as an important process
promoting tumor metastasis and malignancy. Expression of
proteins that are characteristic of mesenchymal cells (e.g. vimentin,
FSP1/S100A4, SNAI1, SNAI2, and stromelysin-3) and loss of
epithelial markers (e.g. E-cadherin) correlates with tumor
progression and poor prognosis [17]. Study shows that invasion
of adenocarcinomas is accompanied by the release of single cells
through EMT [18], suggesting that EMT plays a key role in
malignant cell invasion. Several metastasis-related genes, such as
HOXB7 [19], FOXC2 [20] and Twist [21] have been identified
being able to initiate EMT these years. However, distinguished
from the genes related with EMT mentioned above, Cathepsin Z
existed as a secreted protein and no report showed it has
transcriptional property, thus the EMT phenotype induced by
CTSZ overexpression may not be due to the transcriptional
regulation of EMT markers. Since CTSZ has been suggested to
take part in proteinase degradation [22], the EMT related
phenotype reported in our study could result from epithelial
marker degradation, although further study was still needed to
identify the exact substrates of CTSZ. A non-transcriptional EMT
pathway has also been reviewed by Xu and colleagues [23].
Matrix metalloproteinases (MMPs) have long been associated
with cancer-cell invasion and metastasis. MMPs are proteolytic
enzymes and their basic mechanism of action is to degrade proteins
in extracellular matrix. Activation of MMPs has been detected in
almost all type of human cancer and closely correlated with
advanced tumor stage, increased invasion and metastasis, and
shortened survival time. MMP2, MMP3 and MMP13 have been
found topromote invasion ofcell linesthrougheithercollagentype I
Figure 2. CTSZ processes strong tumorigenicity. (a) Expression of CTSZ in stably transfected QGY-7703 clones (C1 and C2) was detected by RT-
PCR. Empty vector-transfected cells (Vec) were used as control. (b) XTT assay showed that no obvious difference was observed in cell growth rate
between CTSZ-transfectants and Vec-7703 cells. (c) Representatives of colony formation in soft agar (left). The frequency of colony formation between
CTSZ-C1, CTSZ-C2 and Vec-7703 cells was summarized in the right panel. Data were collected from three independent experiments. * P=0.000.
doi:10.1371/journal.pone.0024967.g002
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ribozyme could reduce the number of metastatic nodules formed in
the lungs of mice [25]. Therefore, another mechanism of CTSZ in
tumor metastasis is associated with its role in reducing cell-cell
adhesion by digesting the extracellular matrix ingredients, thus
makes it easier for tumor cells to migrateto the adjacent tissues. The
protease activity may also facilitate the intravasation and extrava-
sation processes. The pro-metastatic role of CTSZ may serve as
another clue to the development of cancer therapy, especially the
inhibition of metastasis. As CTSZ is a secreted protein, it is highly
possible to develop a neutralizing antibody for aborting its protease
activity and thus slower or suppress the metastasis process.
Materials and Methods
Ethics statement
Human tissue samples used in this study were approved by the
Committees for Ethical Review of Research involving Human
Subjects at Cancer Center of Sun Yat-Sen University. Written
informed consent were obtained from all participants involved in
this study. Animal operation was carried out according to the
protocols approved by the Committee on the Use of Live Animals
in Teaching and Research (CULATR). License to conduct live
animal experiments was approved by Hong Kong Department of
Health (lisence no. (09-64) in DH/HA&P/8/2/3 Pt.10).
Figure 3. CTSZ promotes cell motility in HCC cells. (a) Representative images of the Matrigel invasion assay. The cells that invaded through the
Matrigel were fixed and stained with crystal violet (2006magnification). Number of invaded cells was counted in 10 fields under 206objective lens
and summarized in the right panel. **P=0.000. (b) The cell migration rate between CTSZ-C1 and Vec-7703 cells was compared by wound-healing
assay. Microscopic observation was recorded at 0, 12 and 24 hours after scratching the cell layer. (c) Cell adhesion was assessed by seeding 1000 cells
into 96-well plate, and washed with PBS at 30 and 60 minutes. Cells that adhesive to the plate were then stained with crystal violet and counted. Data
were collected from three independent experiments. *P=0.021,* * P=0.002.( d) Representatives of metastatic nodules on the surface of the liver in
SCID mice induced by injecting 3610
5 cells (either CTSZ-7703 or Vec-7703 cells) intravenously. Mice were sacrificed one month after injection, and
H&E staining of liver were shown in the middle panel. Nodules formed in livers were counted and summarized in the right panel. **P=0.000. Data
were collected from three independent experiments.
doi:10.1371/journal.pone.0024967.g003
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Human HCC cell line QGY-7703 was obtained from the
Institute of Virology, Chinese Academy of Medical Sciences
(Beijing, China). Forty-five HCC patients, who underwent hepa-
tectomy for HCC at the Cancer Center of Sun Yat-Sen University
(Guangzhou, China), were included in this study. None of these
patients received preoperative chemotherapy or radiotherapy.
RT-PCR and quantitative real-time PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen,
Carlsbad, CA), and reverse transcription was performed using an
Advantage RT-for-PCR Kit (Clontech Laboratories, Mountain View,
CA, USA) according to the manufacturer’s instructions. For
quantitative real-time PCR (qPCR) analysis, aliquots of double-
stranded cDNA were amplified using a SYBR Green PCR Kit
(Applied Biosystems, Foster City, CA) and an ABI PRISM 7900
Sequence Detector. The cycling parameters were 95uC for 30 s, 55uC
for 1 min and 72uC for 2 min for 45 cycles, followed by a melting
curve analysis. The threshold cycle (CT) was measured during the
exponential amplification phase, and the amplification plots were
analyzed by SDS 1.9.1 software (Applied Biosystems, Foster City,
CA).Primers used are asfollowed,CTSZ:F-59AGAGTGCCACGC-
CATCC 39,R - 5 9 CGCCCTTCCCATCCTTAT 39; 18S: F-59
CTCTTAGCTGAGTGTCCCGC 39,R - 5 9 CTGATCGTCTTC-
GAACCTCC 39; MMP2: F-59 CTTCCAAGTCTGGAGC-
GATGT 39,R - 5 9 TACCGTCAAAGGGGTATCCAT 39; MMP3:
F-59 CAGTTTGCTCAGCCTATC 39,R - 5 9 CAGAGTGTCG-
GAGTCCAG 39; MMP9:F-59 GGGACGCAGACATCGTCATC
39,R - 5 9 TCGTCATCGTCGAAATGGGC 39.
In vitro oncogenic assays
To test the oncogenic function of CTSZ, full-length CTSZ
sequence was amplified by PCR with primers listed in material
and methods. Purified PCR product was cloned into
pCDNA3.1(+) expression vector (Invitrogen, Carlsbad, CA), and
then stably transfected into QGY-7703 cells (CTSZ-7703) with
Lipofectamine2000 (Invitrogen, Carlsbad, CA) according to
manufacturer’s instruction. Clones (C1 and C2) with G418
Figure 4. Overexpression of CTSZ induces epithelial-mesenchymal transition and upregulates MMP2, MMP3 and MMP9. (a)
Expressions of epithelial markers (E-cadherin, a-catenin and b-catenin) and mesenchymal markers (N-cadherin and fibronectin) were compared by
Western blot analysis between CTSZ-7703 and Vec-7703 cells. Beta-actin was used as loading control. (b) Downregulation of epithelial markers (E-
Cadherin and a-catenin) and upregulation of mesenchymal marker vimentin were detected by immunofluorescence in CTSZ-7703 cells compared to
Vec-7703 cells. (c) Representatives of cell morphological changes after introduction of CTSZ into QGY-7703 cells (left). F-actin was stained with
fluorescein isothiocyanate conjugated phalloidin (right) and the formation of filopodia (indicated by arrows) could be detected in CTSZ-7703 cells but
not in Vec-7703 cells. (d) Overexpression of CTSZ could upregulate MMP2, MMP3 and MMP9 expression detected by qPCR. (e) CTSZ overexpression
and MMP9 upregulation in CTSZ-C1 and CTSZ-C2 was confirmed by western blot. **P=0.000. All data were collected from three independent
experiments.
doi:10.1371/journal.pone.0024967.g004
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QGY-7703 cells (Vec-7703) were used as control. Cell growth rate
and colony formation in soft agar were carried out as described
previously [26].
Cell migration and invasion assays
Cell invasion assay was performed with precoated cell invasion
kit (Chemicon International, Temecula, CA). Cells that had
invaded through the extracellular matrix layer to the lower surface
of the membrane were fixed with methanol and stained with
crystal violet. Images of 3 randomly selected fields of the fixed cells
were captured and cells were counted. Experiments were repeated
independently three times. For the wound healing assay, cells were
cultured to 90% confluency when a wound was made by tips.
Pictures from the same area of wound were taken at 0, 12 and
24 hours under microscope after scraping.
Tumor xenograft mouse model
Five-week-old male severe combined immunodeficient (SCID-
Beige) mice were used for tumor xenograft mouse model. CTSZ-
7703 (C1 or C2) or Vec-7703 cells (3610
5) were injected to SCID
mice though tail vain, respectively (3 mice for each group). Mice
were sacrificed 4 weeks after injection. The presence of tumor
nodules was macroscopically determined, and the number of
tumor nodules formed on the liver surfaces was counted. The
livers were excised and embedded in paraffin. Sections (5 mm) of
liver were stained with hematoxyline and eosin (H&E) to visualize
the tumor structure. All animal procedures were performed in full
accordance with CULATR-approved protocol.
Western blot analysis
Western blot analysis was performed as described previously (9)
with antibodies for CTSZ, vimentin, fibronectin, E-cadherin and
b-actin (Santa Cruz Biotechnology, Santa Cruz, CA), N-cadherin,
b-catenin and a-catenin (Cell Signalling Technology, Germany).
Immunofluorescent (IF) microscopy
For IF staining, cells were seeded onto coverslips, incubated
overnight and then fixed with 4% paraformaldehyde. Fixed cells
were incubated with 1:2000 fluorescein isothiocyanate-conjugated
phalloidin (Sigma, St. Louis, MO) or antibodies as indicated. Cells
were then mounted with Mounting Medium containing DAPI
(Vector Laboratories, Burlingame, CA). Images were captured by
a Leica DMRA fluorescence microscope (Leica, Wetzlar,
Germany).
Immunohistological chemistry staining
Tissue slides were dewaxed according to standard protocol.
Briefly, slides were dewaxed in 70uC incubator followed by
abosolute xylene rinse for 10 mins. Rehydration of slides were
carried out by serially rinsing slides in 100%, 95%, 80% and 50%
(v/v) ethanol for 5 mins each. Antigen retrieval was done by
boiling slides in antigen retrieval buffer for 15 mins and cooling
naturally. Primary antibody was added to the tissues on the slides
and incubated at 4uC overnight. Secondary antibody was added
for 1 hour after rinsing by PBS. DAB was used for staining.
Statistical analysis
The SPSS statistical package for Window version 13 (SPSS,
Chicago, IL) was used for data analysis. RQ of CTSZ in tumor
and nontumor samples were compared using paired T-test. The
clinicopathological features of patients with or without CTSZ
upregulation were compared using Pearson’s chi-square test for
categorical variables. The survival curves of patients with or
without CTSZ upregulation was calculated by Kaplan-Meier
method. A p value less than 0.05 was considered statistically
significant.
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